Laboratory Andrology Equipment Market Size, Share, and Growth Forecast 2026 - 2033

Laboratory Andrology Equipment Market by Equipment Type (Semen Analysis Systems, Sperm Centrifuges, Andrology Microscopes, Sperm Counting Chambers, Sperm Preparation and Processing Equipment, Others), Testing Type, End-User, and Regional Analysis for 2026-2033

ID: PMRREP38493
Calendar

October 2026

198 Pages

Author : Vaishnavi Patil

Laboratory Andrology Equipment Market Size and Trends Analysis

The global laboratory andrology equipment market is expected to be valued at US$ 945.0 million in 2026 and is projected to reach US$ 1,294.7 million by 2033, growing at a CAGR of 4.6% between 2026 and 2033.

The market is experiencing steady growth as male factor infertility is increasingly recognized as a major component of reproductive health, and accurate laboratory evaluation is an essential starting point for fertility assessment and treatment. The World Health Organization (WHO) estimates that about 1 in 6 people worldwide experience infertility, while clinical bodies such as the American Society for Reproductive Medicine (ASRM) recognize male factors as contributing to roughly half of infertility cases.

At the same time, a meta-analysis published in Human Reproduction Update in 2023 reported a global decline in sperm concentration of more than 50% between 1973 and 2018. Rising assisted reproductive technology (ART) volumes, evolving laboratory standards, and the adoption of computer-assisted semen analysis (CASA), advanced sperm function tests, and cryostorage systems are expanding equipment demand across fertility clinics, hospitals, and diagnostic laboratories.

Key Industry Highlights

  • Leading Region: North America is likely to lead the global laboratory andrology equipment market with around 39% share in 2026, supported by high ART volumes, established laboratory accreditation practices, demand for post-vasectomy semen analysis, and strong adoption of automated semen analysis systems.
  • Fastest-growing Region: Asia Pacific represents the fastest-growing market, driven by expanding fertility clinic networks, evolving ART regulations, increasing access to fertility services, and healthcare investment across Japan, China, and India.
  • Dominant Segment: Routine semen analysis is the leading testing segment, holding around 36% share in 2026, supported by its role as a first-line evaluation for male infertility and its use in fertility assessments and post-vasectomy testing.
  • Fastest-growing Segment: Sperm DNA fragmentation testing is the fastest-growing segment, driven by growing clinical interest in sperm DNA integrity assessment, particularly in selected cases involving recurrent pregnancy loss, unexplained infertility, and repeated ART failure.
  • Key Market Opportunity: AI-enabled CASA platforms and advanced sperm selection technologies offer strong growth potential by improving analytical consistency, enhancing laboratory efficiency, and supporting sperm assessment and selection during IVF and ICSI procedures.

laboratory-andrology-equipment-market-size-2026-2033

See exactly what you're buying — Before you spend a dollar.

Get a free sample copy of our market report: data, tables, charts, research depth, analyst insights, and relevance of our research - all in hand before you commit.

Market Dynamics

Drivers - Rising Male Infertility and Declining Semen Quality

Growing evidence of deteriorating male reproductive health is a major driver of andrology equipment demand. A 2023 meta-analysis published in Human Reproduction Update, covering data from 53 countries, found that mean sperm concentration fell by 51.6% between 1973 and 2018, with the rate of decline accelerating to more than 2.6% per year after 2000. The WHO reports that infertility affects about 17.5% of the adult population globally, and the American Urological Association (AUA) and ASRM joint guideline on male infertility recommends that the male partner undergo evaluation, including semen analysis, when a couple experiences infertility.

Lifestyle factors such as obesity, smoking, and delayed parenthood are adding to the patient pool. This expanding diagnostic workload drives purchases of semen analyzers, microscopes, counting chambers and centrifuges across clinical and specialty laboratories.

Growth of Assisted Reproduction and Laboratory Standardization

Rising assisted reproductive technology (ART) volumes and stricter quality standards are increasing investment in validated andrology equipment. The U.S. Centers for Disease Control and Prevention (CDC) reports more than 400,000 ART cycles annually in the U.S., while the European Society of Human Reproduction and Embryology (ESHRE) records more than one million treatment cycles each year in Europe. Every IVF and ICSI cycle requires semen evaluation and sperm preparation using centrifuges, incubators, and processing equipment.

Standardization is also intensifying: the WHO Laboratory Manual for the Examination and Processing of Human Semen, 6th edition, published in 2021, and the international standard ISO 23162:2021 define methods for basic semen examination. Accreditation programs such as the College of American Pathologists (CAP) Reproductive Laboratory Accreditation Program encourage laboratories to adopt calibrated, traceable systems, supporting replacement of outdated manual equipment.

Restraints - High Equipment Costs and Budget Constraints

The high cost of advanced andrology systems limits adoption, especially among small laboratories and clinics in emerging markets. Computer-assisted semen analysis (CASA) platforms, phase contrast microscopes, controlled-rate freezers and liquid nitrogen storage systems require significant capital investment, along with ongoing costs for software licenses, calibration, service contracts and consumables. Many smaller laboratories perform relatively low volumes of semen analyses, making it difficult to justify the investment compared with manual microscopy using counting chambers.

In public health systems, procurement priorities often favor female infertility treatment and general diagnostic equipment over specialized male fertility tools. Reimbursement for semen analysis is generally modest, and advanced tests such as sperm DNA fragmentation are frequently self-paid, limiting return on investment and delaying equipment upgrades in price-sensitive healthcare systems across Asia, Latin America and Africa.

Opportunities - Sperm DNA Fragmentation Testing and Advanced Sperm Selection

Rising demand for sperm DNA fragmentation (SDF) testing represents a significant opportunity for equipment and assay suppliers. Conventional semen parameters do not fully predict fertility outcomes, and research has linked high DNA fragmentation to lower pregnancy rates and recurrent pregnancy loss. The European Association of Urology (EAU) guidelines on sexual and reproductive health recommend SDF testing in couples with recurrent pregnancy loss or recurrent ART failure, and the AUA/ASRM guideline notes its potential value in selected cases.

These recommendations are encouraging laboratories to adopt flow cytometry, fluorescence microscopy and sperm chromatin dispersion systems. Demand is also growing for sperm preparation and processing equipment, including microfluidic sperm sorting devices that select sperm with lower DNA damage. Suppliers that combine validated assays, imaging platforms and interpretation software can build recurring revenue from consumables and testing services.

Category-wise Analysis

Equipment Type Insights

Semen analysis systems are the leading equipment type category, holding about 27% market share in 2026. Semen analysis is the cornerstone of male fertility evaluation and is recommended as a first-line test by the WHO, AUA/ASRM, and EAU guidelines. Automated and computer-assisted platforms, such as the IVOS II and CEROS II systems from Hamilton-Thorne, the SCA system from Microptic, and the SQA-Vision analyzer from Medical Electronic Systems, are used in fertility clinics and diagnostic laboratories.

These systems provide standardized measurements of sperm concentration, motility, and morphology, supporting laboratory assessment in accordance with the WHO 6th edition manual while reducing subjectivity and improving throughput. Their higher unit value compared with counting chambers and basic microscopes also supports revenue leadership.

Sperm preparation & processing equipment is projected to be the fastest-growing segment, driven by increasing adoption of microfluidic sperm selection technologies and established sperm preparation methods, including density gradient centrifugation, for assisted reproductive procedures such as ICSI.

Testing Type Insights

Routine semen analysis is the leading testing type segment, holding about 36% share of the market in 2026. Routine analysis, covering volume, pH, concentration, motility, and vitality, is a first-line assessment for male infertility and is commonly performed during fertility evaluations before IVF and ICSI procedures. The WHO 6th edition manual reports lower fifth-percentile reference values, including a sperm concentration of 16 million per millilitre and total progressive motility of 30%, which laboratories use as reference points when interpreting results.

Routine semen analysis is also used after vasectomy to confirm procedural success; around 500,000 vasectomies are performed in the U.S. annually, creating additional demand for post-procedure semen testing. This high testing volume sustains demand for microscopes, counting chambers, centrifuges, and automated analyzers.

Sperm DNA fragmentation testing is expected to be the fastest-growing testing type, supported by increasing clinical interest in sperm DNA integrity assessment for selected cases involving recurrent pregnancy loss, unexplained infertility, and repeated ART failure.

End-User Insights

Fertility clinics and IVF centers are the dominant end-user category, with an estimated 41% market share in 2026. These centers combine diagnostic semen analysis with sperm preparation, ICSI, cryopreservation, and sperm banking, making them major users of andrology equipment, from CASA systems and centrifuges to incubators and liquid nitrogen storage dewars. The CDC collects ART data from hundreds of fertility clinics in the U.S., while the expansion of multi-site fertility networks supported by private investment has created large buyers that standardize equipment across locations.

Clinics also use advanced sperm function and DNA fragmentation testing in selected cases to support clinical decision-making. Accreditation programs such as CAP and regulatory bodies, including the Human Fertilisation and Embryology Authority (HFEA), encourage investment in validated equipment and quality management systems.

Andrology laboratories are projected to register the fastest growth as demand for specialized male fertility testing expands, supported by increasing emphasis on diagnostic accuracy, specialized sperm function assessment, and laboratory services for fertility clinics and hospitals.

laboratory-andrology-equipment-market-outlook-by-testing-type-2026-2033

Not every business fits the same mold. Your research shouldn't either.

Connect with the team for a customization and get a one-of-a-kind report scoped to your niche — The insights your competitors won't have access to.

Regional Analysis

North America Laboratory Andrology Equipment Market Trends and Insights

North America is expected to lead the global laboratory andrology equipment market with around 39% share in 2026, supported by high ART utilization, well-funded fertility clinics, and strong adoption of automated semen analysis systems. Laboratory quality requirements under CLIA and voluntary CAP accreditation encourage use of calibrated equipment. Key regional trends include growing awareness of male reproductive health, expansion of men's health clinics and telehealth services offering semen testing and sperm cryostorage, and increasing use of sperm DNA fragmentation testing in couples with recurrent IVF failure.

Employer-sponsored fertility benefits that cover male evaluation and sperm freezing are widening access. The region also hosts major sperm banks and academic andrology centers that drive research and early adoption of AI-based analysis tools. Canada contributes further demand through publicly funded fertility programs in provinces including Ontario and Quebec.

U.S. Laboratory Andrology Equipment Market Size

The U.S. accounts for around 89% of North American market revenue. Demand is supported by more than 400,000 ART cycles annually reported by the CDC and about 500,000 vasectomies each year cited by the AUA, each generating semen testing volume. The AUA/ASRM male infertility guideline reinforces semen analysis as a first-line evaluation. Growth opportunities are emerging from sperm banking for fertility preservation, recommended for men facing cancer treatment by the American Society of Clinical Oncology (ASCO), and from expanding employer fertility benefits.

The U.S. Food and Drug Administration (FDA) has cleared home semen screening products, increasing awareness and referrals to laboratories for confirmatory testing using advanced analyzers. Strong private investment in fertility clinic networks further accelerates equipment upgrades.

Europe Laboratory Andrology Equipment Market Trends and Insights

Europe represents a mature and highly standardized market, supported by the world's largest reported ART volumes, with ESHRE recording more than one million treatment cycles annually. Strong guidance from ESHRE and the European Association of Urology (EAU), along with external quality assessment programs, drives consistent laboratory practice. Key regional trends include adoption of ISO 23162:2021 for semen examination, growing use of sperm DNA fragmentation testing, and investment in automated CASA platforms to reduce variability.

The EU In Vitro Diagnostic Regulation (IVDR) is increasing documentation requirements for diagnostic devices and assays, favoring established suppliers. Public funding for fertility treatment in many countries sustains steady equipment demand, while cross-border reproductive care in Spain, Greece, and the Czech Republic supports high-volume laboratory activity.

Germany Laboratory Andrology Equipment Market Size

Germany is expected to hold around 20% share of the European market in 2026. The German IVF Registry (D·I·R) reports more than 100,000 treatment cycles annually, with ICSI accounting for a large share of procedures, generating high demand for sperm preparation equipment. Laboratory quality is governed by the German Medical Association's quality assurance guideline, known as Rili-BÄK, encouraging use of validated analyzers. Statutory health insurance covers 50% of costs for up to three IVF or ICSI cycles for eligible couples, supporting stable volumes.

Germany also has a strong tradition of andrology as a medical specialty, supported by the German Society of Andrology, and a robust medical technology industry, including optical leaders such as ZEISS. Rising demand for sperm DNA fragmentation testing creates additional upgrade opportunities.

U.K. Laboratory Andrology Equipment Market Size

The U.K. is projected to hold about 15% share of the European market revenue. The HFEA regulates all licensed fertility clinics and sperm banks, and reports around 76,000 IVF cycles annually. The Association of Biomedical Andrologists (ABA) and the UK NEQAS andrology scheme promote standardized semen analysis and external quality assessment, encouraging adoption of reliable equipment. The HFEA extension of the statutory storage limit for frozen sperm, eggs and embryos to up to 55 years from July 2022 supports long-term investment in cryopreservation and storage equipment.

Opportunities are growing in sperm banking for fertility preservation and in private clinics offering advanced sperm function testing, while variation in NHS funding drives private sector growth. Expanding demand for donor sperm further supports investment in screening and storage equipment.

Asia Pacific Laboratory Andrology Equipment Market Trends and Insights

Asia Pacific represents the fastest-growing market, supported by large patient populations, rising awareness of male infertility and rapid expansion of fertility clinics. China is the region's largest market, with the National Health Commission overseeing hundreds of licensed ART institutions and human sperm banks. Births in China fell to about 9.02 million in 2023, according to the National Bureau of Statistics, prompting pro-natal policies and the gradual inclusion of ART services in local medical insurance schemes.

Across the region, clinics are investing in CASA systems, ICSI workstations and cryostorage to meet growing demand. Medical tourism hubs in Thailand, Malaysia and India attract international patients, while strengthening regulatory frameworks encourage replacement of manual methods with standardized, validated andrology equipment. Growing male infertility awareness campaigns are also increasing semen testing volumes across the region.

India Laboratory Andrology Equipment Market Size

India is projected to hold about 13% share of the Asia Pacific market in 2026. Infertility affects an estimated 27.5 million couples, according to figures widely cited by the Indian Council of Medical Research (ICMR), with male factors contributing significantly. The Assisted Reproductive Technology (Regulation) Act, 2021 requires registration of ART clinics and semen banks through a national registry, raising laboratory standards and driving equipment upgrades.

Large fertility chains are expanding rapidly into tier-2 and tier-3 cities, increasing demand for semen analyzers, centrifuges, and cryostorage equipment. Domestic manufacturers such as Shivani Scientific Industries offer cost-effective laboratory equipment, while India's position as an affordable IVF destination supports further growth in andrology testing volumes. Rising awareness of male infertility in urban centers is also increasing referrals for advanced sperm function testing.

Japan Laboratory Andrology Equipment Market Size

Japan is estimated to capture 25% of the regional market share. According to the Japan Society of Obstetrics and Gynecology (JSOG), nearly 500,000 ART cycles are performed annually, and roughly 1 in 10 babies is born through ART. The extension of public health insurance to infertility treatment from April 2022, including selected male infertility procedures such as testicular sperm extraction, has increased male evaluation and treatment volumes.

Japan's highly developed laboratory infrastructure and emphasis on precision support adoption of automated CASA systems and high-quality microscopes from domestic and international suppliers. Growing government attention to declining birth rates and local subsidies for fertility testing create further opportunities for andrology equipment suppliers. Strong local optical and imaging companies also support adoption of high-precision microscopy for morphology assessment.

laboratory-andrology-equipment-market-outlook-by-region-2026-2033

Competitive Landscape

The global laboratory andrology equipment market is moderately fragmented, combining specialized male fertility companies with diversified laboratory equipment manufacturers. Specialists such as Nexpring Health, which brings together the Hamilton Thorne and Microptic CASA brands, and Medical Electronic Systems lead in semen analysis systems through validated software, WHO-aligned methods, and installed bases in fertility clinics. Diversified companies including Thermo Fisher Scientific and ZEISS compete in centrifuges, incubators, cryostorage and microscopy.

Regional manufacturers such as Shivani Scientific Industries compete on price in emerging markets. Key strategies include AI-based image analysis, integrated laboratory workflows, acquisitions to complete portfolios, and expansion of distribution in Asia Pacific. Emerging business models include software subscriptions, consumable-linked pricing and bundled service contracts for multi-site clinic networks, supported by remote technical service.

Key Industry Developments

  • In September 2026, Shinelife Meditec LLP highlighted its expanding fertility MedTech portfolio in India, covering IVF and andrology laboratory equipment, benchtop incubators, cryopreservation devices, fertility-preservation solutions, and laboratory quality-control systems.
  • In November 2024, Basecare Medical announced the market approval of its BKA210 Intelligent Sperm Quality Analyzer in China (NMPA No. 20242222101). The AI-powered device analyzes sperm morphology, concentration, and vitality in unstained live sperm samples, with results available in as little as three minutes.

Companies Covered in Laboratory Andrology Equipment Market

  • Nexpring Health (Hamilton Thorne and Microptic)
  • Shivani Scientific Industries Pvt. Ltd.
  • Medical Electronic Systems LLC
  • Thermo Fisher Scientific Inc.
  • ZEISS
  • Others
Frequently Asked Questions

The global market is expected to be valued at US$ 945.0 million in 2026.

Demand is driven by rising male infertility, declining semen quality reported in global studies, growing IVF and ICSI volumes, and stricter laboratory standards such as the WHO 6th edition manual and ISO 23162:2021.

North America is likely to lead the global market while holding around 39% share in 2026.

Rising demand for sperm DNA fragmentation testing, AI-enabled CASA systems, and advanced sperm selection technologies, along with fertility clinic expansion in Asia Pacific, offers the most significant growth opportunities.

Key players include Nexpring Health (Hamilton Thorne and Microptic), Medical Electronic Systems, Thermo Fisher Scientific, ZEISS, Shivani Scientific Industries, CooperSurgical, and Vitrolife Group.

UK

Corporate Office

Persistence Research & Consultancy Services Limited

Company Number : 15310893

Second Floor, 150 Fleet Street,London, EC4A 2DQ.

+44 203-837-5656
USA

Regional Office

Persistence Market Research

108 W 39th Street, Ste 1006,PMB2219, New York, NY 10018

+1 646-878-6329
India

Global Research centre

Persistence Market Research Private Limited

CIN : U74900PN2014PTC153163

6th Floor, Teerth Technospace, Teerth Realties, Office No. B- 604, Baner, Pune, Maharashtra 411045

Copyright © 2026 Persistence Market Research. All Rights Reserved

Connect With Us -